Emerging properties of cannabinoid medicines in management of multiple sclerosis
- 31 May 2005
- journal article
- review article
- Published by Elsevier in Trends in Neurosciences
- Vol. 28 (5) , 272-276
- https://doi.org/10.1016/j.tins.2005.03.006
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trialBMJ, 2004
- Medicinal cannabis: is Δ9–tetrahydrocannabinol necessary for all its effects?Journal of Pharmacy and Pharmacology, 2003
- Anti-spasticity agents for multiple sclerosisCochrane Database of Systematic Reviews, 2003
- Pharmacokinetics and Pharmacodynamics of CannabinoidsClinical Pharmacokinetics, 2003
- International Union of Pharmacology. XXVII. Classification of Cannabinoid ReceptorsPharmacological Reviews, 2002
- Endocannabinoids control spasticity in a multiple sclerosis modelThe FASEB Journal, 2000
- Molecular characterization of a peripheral receptor for cannabinoidsNature, 1993
- Structure of a cannabinoid receptor and functional expression of the cloned cDNANature, 1990
- Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients.Thorax, 1976
- Isolation, Structure, and Partial Synthesis of an Active Constituent of HashishJournal of the American Chemical Society, 1964